Two China IPOs Accepted: PCB Materials Firm Liuxin Targets ChiNext, Feed Biotech Anyou Eyes Main Board

The Quick Take

• Liuxin Shares, a PCB precision drilling materials firm, wins ChiNext IPO acceptance targeting ¥569M in fundraising.
• Anyou Biotech, a livestock precision nutrition company, wins main board IPO acceptance targeting ¥810M from investors.
• Both companies plan to fund production expansion, digital infrastructure, and new R&D centers from IPO proceeds.

China's domestic IPO acceptance pipeline reflects the CSRC's careful calibration of new equity supply after years of reform aimed at market stability. The two accepted applications — Liuxin Shares for printed circuit board functional materials on ChiNext, and Anyou Biotech for animal nutrition on the Main Board — represent strategic industrial sectors that Chinese regulators prioritize under dual-circulation and technology self-reliance policies. PCB materials are directly linked to China's semiconductor and electronics supply chain modernization, while precision animal nutrition aligns with food security priorities under the 14th Five-Year Plan and supports rural income stabilization goals.

For investors in China's A-share market, IPO acceptance marks the start of a multi-month review process before actual listing, making these medium-term capital events rather than immediate price catalysts. The combined ¥1.38 billion (approximately $190 million USD) in fundraising targets is consistent with ChiNext and Main Board mid-cap listing norms. Comparable PCB materials companies listed on A-shares — including Shengyi Technology — would face marginal competitive pressure if Liuxin successfully executes its factory and R&D expansion. Anyou Biotech's digital feed formulation investment positions it against New Hope Group and Haid Group in China's consolidating livestock nutrition market.

Watch the CSRC review timeline: typical approval processes for ChiNext and Main Board applications take three to six months from acceptance, with one to two rounds of supplementary inquiries common. The macro variable is A-share market sentiment — if the CSI 300 sustains recovery above 4,200, IPO pricing conditions improve and both companies' offering valuations expand. Investors should monitor China's agricultural policy for any livestock producer subsidy program that would boost Anyou Biotech's near-term revenue, and track PCB sector demand data from Shenzhen's electronics industry as a leading indicator for Liuxin's commercial timing.

Synthesized from 2 sources.